Luxembourg
· Delayed Price · Currency is EUR · Price in USD Oneness Biotech Statistics
Total Valuation
Oneness Biotech has a market cap or net worth of EUR 861.76 million. The enterprise value is 689.79 million.
| Market Cap | 861.76M |
| Enterprise Value | 689.79M |
Important Dates
The last earnings date was Tuesday, May 13, 2025.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.01% |
| Shares Change (QoQ) | -0.25% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 305.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 264.14 |
| PB Ratio | 2.57 |
| P/TBV Ratio | 2.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -20.09 |
| EV / Sales | 200.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -72.70 |
Financial Position
The company has a current ratio of 43.04, with a Debt / Equity ratio of 0.03.
| Current Ratio | 43.04 |
| Quick Ratio | 42.04 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.16 |
| Interest Coverage | -108.07 |
Financial Efficiency
Return on equity (ROE) is -9.38% and return on invested capital (ROIC) is -4.68%.
| Return on Equity (ROE) | -9.38% |
| Return on Assets (ROA) | -4.54% |
| Return on Invested Capital (ROIC) | -4.68% |
| Return on Capital Employed (ROCE) | -7.97% |
| Revenue Per Employee | 75,872 |
| Profits Per Employee | -798,501 |
| Employee Count | 43 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.54 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.78% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -56.78% |
| 50-Day Moving Average | 10.50 |
| 200-Day Moving Average | 17.06 |
| Relative Strength Index (RSI) | 52.08 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oneness Biotech had revenue of EUR 3.26 million and -34.34 million in losses. Loss per share was -0.07.
| Revenue | 3.26M |
| Gross Profit | 1.50M |
| Operating Income | -28.25M |
| Pretax Income | -34.24M |
| Net Income | -34.34M |
| EBITDA | -17.92M |
| EBIT | -28.25M |
| Loss Per Share | -0.07 |
Balance Sheet
The company has 188.03 million in cash and 11.01 million in debt, giving a net cash position of 177.02 million.
| Cash & Cash Equivalents | 188.03M |
| Total Debt | 11.01M |
| Net Cash | 177.02M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 335.86M |
| Book Value Per Share | 0.67 |
| Working Capital | 190.74M |
Cash Flow
In the last 12 months, operating cash flow was -8.58 million and capital expenditures -904,846, giving a free cash flow of -9.49 million.
| Operating Cash Flow | -8.58M |
| Capital Expenditures | -904,846 |
| Free Cash Flow | -9.49M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 46.04% |
| Operating Margin | -865.94% |
| Pretax Margin | -1,049.56% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Oneness Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.01% |
| Shareholder Yield | 0.01% |
| Earnings Yield | -3.98% |
| FCF Yield | -1.10% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |